BMS reports flat revenue growth for full-year 2025
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas.
Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn.
AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.
Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and potential commercialisation of its botensilimab and balstilimab (BOT/BAL) immunotherapy combination programme.
BD (Becton, Dickinson and Company) has announced a $110m investment to expand its production of prefillable syringes in the US.
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea.
Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in Europe.
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa therapy.
Formosa Pharmaceuticals and Rxilient Medical have signed an exclusive licensing agreement for the commercialisation of Byqlovi, clobetasol propionate ophthalmic suspension, 0.05% (APP13007), in the Association of Southeast Asian Nations (ASEAN) markets.